CROS NT Ltd Announces Acquisition of MDSL International Ltd.
As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International
As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International - a specialist clinical Contract Research Organization (CRO) providing biometrics services such as Clinical Data Management and Statistical services. The financial details of the transaction remain confidential.
CROS NT Ltd, the UK branch of CROS NT, sees the acquisition as an important part of the overall group strategy. The deal adds additional resources to the existing group in the UK and will provide a new headquarters for the UK company in Maidenhead, close to London. MDSL International has built a reputation for providing strong consultancy and project work coupled with excellent customer service.
Andrew MacGarvey,
Edmund Otun, the founder of MDSL International, said, "I am pleased to have concluded the deal with CROS NT. Being part of a larger entity allows us to provide additional resources to our existing clients - something they have been asking for. CROS NT has a very strong management team, with great experience in the CRO business. I will remain with the company providing consultancy for emerging companies seeking advice on getting their products to market or securing licencing deals."
Jo Marshall, MDSL International Managing Director, who will become the UK Country Manager for CROS NT Ltd added, "I am excited by this opportunity and looking forward to working with the CROS NT team. In addition to giving us greater critical mass here in the UK, this deal will give our existing customers access to the CROS NT technology portfolio which includes several
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025